Abstract
The retinoblastoma tumor suppressor (RB) is functionally inactivated at high frequency in human cancers. Based on the role of RB as a negative regulator of cell cycle this event would be expected to contribute to deregulated proliferation. However, evidence suggests that loss of RB not only mediates aberrant proliferation, but compromises the fidelity of cell cycle transitions leading to a breakdown in genome integrity. This review is focused on the mechanisms underlying this facet of RB function and the contibution of this process to tumorigenesis.
Keywords: Cell Cycle, E2F pathway, RB interaction, Centrosome Duplication Cycle, DNA replication
Current Molecular Medicine
Title: Role of the Retinoblastoma Tumor Suppressor in the Maintenance of Genome Integrity
Volume: 6 Issue: 7
Author(s): Erik S. Knudsen, Charlene R. Sexton and Christopher N. Mayhew
Affiliation:
Keywords: Cell Cycle, E2F pathway, RB interaction, Centrosome Duplication Cycle, DNA replication
Abstract: The retinoblastoma tumor suppressor (RB) is functionally inactivated at high frequency in human cancers. Based on the role of RB as a negative regulator of cell cycle this event would be expected to contribute to deregulated proliferation. However, evidence suggests that loss of RB not only mediates aberrant proliferation, but compromises the fidelity of cell cycle transitions leading to a breakdown in genome integrity. This review is focused on the mechanisms underlying this facet of RB function and the contibution of this process to tumorigenesis.
Export Options
About this article
Cite this article as:
Knudsen S. Erik, Sexton R. Charlene and Mayhew N. Christopher, Role of the Retinoblastoma Tumor Suppressor in the Maintenance of Genome Integrity, Current Molecular Medicine 2006; 6 (7) . https://dx.doi.org/10.2174/1566524010606070749
DOI https://dx.doi.org/10.2174/1566524010606070749 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Oligonucleotide-Based Molecular Therapy for Restenosis after Angioplasty
Current Drug Targets Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry A Path to Development or Demise ?
Current Neurovascular Research Cell Cycle Checkpoint Genes and Aneuploidy: A Short Review
Current Genomics Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Current Cancer Drug Targets Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Hsp90: A Novel Target for Cancer Therapy
Current Topics in Medicinal Chemistry Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Perinatal Management of Fetal Tumors
Current Pediatric Reviews Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology TGFb and its Smad Connection to Cancer
Current Genomics Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease
Current Vascular Pharmacology